European Journal of Cardiovascular Medicine

Background: Prostate cancer (PCa) is a major cause of morbidity and mortality among men in the United States and globally. However, many men with prostate cancer have slow growing tumor and experience an indolent course even without curative therapy. The increasing incidence may be due to increased PSA-measurements and other diagnostic efforts. However, this review does not handle the associated differential diagnosis. Also, the biological heterogeneity that characterizes this disease causes decision issues unique to prostate cancer. Low-grade cancer diagnosed late in life may have no impact on the quality or length of life.  Materials and methods: A cross-sectional study was conducted to test the hypothesis of an association of IFN-γ, IL-6 and PSA with obesity parameters for the severity of prostate cancer. Total 90 participants included in study and Anthropometric examination and hormonal test were also performed simultaneously. Among 90 participants; Total 45 participants were grouped in Benign Prostatic Hyperplasia (BPH) and 45 in PCa groups respectively. Serum samples of men with suspicion of prostate cancer based on high prostate specific antigen (PSA) and/or abnormal DRE were withdrawn before biopsy between 8 a.m.  and 11 a.m. Serum PSA, IFN-gamma and IL-6 levels were estimated using ELISA on the same day. The serum was separated, aliquoted and kept frozen at -80ºC for analysis. Result: Waist hip ratio was significantly (p<0.0001) higher in the patients of PCa (2.9 ± 1.43) as compared to BPH (1.92 ± 1.20). Level of IFN-γ was significantly (p<0.0001) higher in PCa (144.6 ± 49.9) patients as compared to BPH patients (61.8 ± 11.9). Similarly, the Interleukin-6 level was significantly (p<0.0001) higher in PCa patients (36.95±11.37) as compared to BPH patients (13.7±9.47). The age of the patients was almost similar in both Lower (68.59±12.15) and Higher (67.70±12.70) grades.  The level of BMI was significantly (p=0.008) higher in the patients of Higher grade (28.35±7.99) as compared to Lower (26.85±5.89) grade.  The higher-grade patients had more risk of being overweight than the lower grade patients (Unadjusted OR=1.14, 95%CI=1.03-1.16). Similarly, the waist-hip ratio was also significantly (p=0.03) higher in the patients of Higher grade (2.33±1.53) as compared to Lower grade (2.09±1.38). Conclusion: The introduction of total PSA in clinical practice has resulted in early detection and reduced mortality from PCa. However, PCa screening remains controversial, because of the risk of over diagnosis reduced mortality and overtreatment and the inability to detect a significant proportion of dangerous tumors. A large concerted effort has been made to improve and/or monitoring the activity of PCa and to guide molecular targeted therapy and/or assess therapeutic response. An integrated approach with blood-based measurement of different molecular forms of PSA in combination with genetic and urine biomarkers hold the promise of improving screening for and diagnosis of PCa. Analysis of panels of blood-based biomarkers will be a significant step towards fingerprinting of the tumors biologic behavior.